Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBM588 with Nivolumab and Ipilimumab in Advanced RCC
NCT06399419Phase 1Recruiting
- Sponsor
- Osel Inc.
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MO-03 in renal cell carcinoma (RCC), sponsored by Osel Inc. Primary endpoints: Dose limiting toxicity at 28 days, Maximum tolerated dose at 28 days and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
MO-03
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06399419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399419.